HomeCYAD • EBR
Follow
Celyad Oncology SA
Previous close
€0.36
Day range
€0.35 - €0.37
Year range
€0.35 - €1.28
Market cap
15.04M EUR
Avg Volume
12.37K
P/E ratio
-
Dividend yield
-
Primary exchange
EBR
Market news
Financials
Income Statement
Revenue
Net income
(EUR) | Jun 2023info | Y/Y change |
---|---|---|
Revenue | 22.00K | — |
Operating expense | 2.40M | -68.83% |
Net income | -1.87M | 71.16% |
Net profit margin | -8.50K | — |
Earnings per share | — | — |
EBITDA | -2.27M | 69.35% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(EUR) | Jun 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 4.98M | -65.41% |
Total assets | 12.18M | -80.71% |
Total liabilities | 11.16M | -65.65% |
Total equity | 1.02M | — |
Shares outstanding | 22.59M | — |
Price to book | 7.10 | — |
Return on assets | -49.35% | — |
Return on capital | -386.49% | — |
Cash Flow
Net change in cash
(EUR) | Jun 2023info | Y/Y change |
---|---|---|
Net income | -1.87M | 71.16% |
Cash from operations | -4.17M | — |
Cash from investing | 482.50K | — |
Cash from financing | -51.00K | — |
Net change in cash | -3.73M | — |
Free cash flow | -1.26M | — |
About
Founded
2004
Headquarters
Website
Employees
37